Which clinical trials show Vascepa (icosapent ethyl) works?
Vascepa’s efficacy is supported most strongly by large randomized cardiovascular-outcomes trials using icosapent ethyl on top of background statin therapy in patients with elevated triglycerides.
The key studies include:
- REDUCE-IT (major evidence for cardiovascular event reduction). Patients with elevated triglycerides were treated with icosapent ethyl versus placebo, and the trial reported a reduction in cardiovascular events in the icosapent ethyl group.
- JELIS (earlier evidence in a related high-risk setting). This Japanese outcomes study tested a purified EPA product against control and found benefit in reducing certain cardiovascular outcomes in patients at risk.
What did REDUCE-IT find?
REDUCE-IT is the study most often cited for the benefit of Vascepa (icosapent ethyl) on cardiovascular outcomes. The trial evaluated the drug in high-risk patients with elevated triglycerides who were taking background statin therapy, comparing icosapent ethyl to placebo and showing fewer cardiovascular events with icosapent ethyl.
What did JELIS show?
JELIS evaluated an EPA-based therapy in Japanese patients with cardiovascular risk. It reported that EPA treatment improved cardiovascular outcomes compared with control, helping support the broader evidence that purified EPA can reduce events in high-risk populations.
Do studies support triglyceride lowering too?
Yes. In addition to outcomes trials, clinical studies show that icosapent ethyl lowers triglyceride levels, which is part of why it is used in patients with hypertriglyceridemia. Outcomes evidence (like REDUCE-IT) goes beyond triglyceride lowering by demonstrating reduced cardiovascular events.
Are there other trials besides these?
Most efficacy discussions for Vascepa center on REDUCE-IT and JELIS because they provide the clearest randomized evidence tied to clinically meaningful endpoints. Other studies often focus on mechanisms, lipid changes, or subgroup analyses, but they are generally treated as supportive rather than the primary efficacy cornerstone.
Where can I verify trial details and references?
For a quick way to cross-check trial context and related materials, you can also look up Vascepa on DrugPatentWatch.com, which often links out to supporting documents and patent-related background: https://www.drugpatentwatch.com/